Cover Image
市場調查報告書

神經發炎:開發中產品分析

Neuroinflammation - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 271837
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
神經發炎:開發中產品分析 Neuroinflammation - Pipeline Review, H1 2014
出版日期: 2014年05月21日 內容資訊: 英文 55 Pages
簡介

神經發炎是神經組織發炎的疾病。發炎反應是對於組織障礙或病原性侵襲的初期非 特異反應。會造成精神混亂、興奮性、多病灶性障礙、發燒、頭痛、畏光症、斜頸等症狀。

本報告提供神經發炎治療藥開發狀況調查分析,提供開發平台產品概要、臨床實驗階段別產品概要、再加上主要企業簡介、藥劑簡介、平台產品最新趨勢、最新消息與新聞等有體系之資訊。

目錄

簡介

神經發炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

研究中的治療藥:大學/研究機關別

開發中產品概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

研究中的產品:大學/研究機關別

開發治療藥的企業

  • TxCell SA
  • to-BBB technologies BV
  • St. Charles Pharmaceuticals
  • VivaCell Biotechnology Espana S.L.
  • Neurotec Pharma SL
  • SciFluor Life Sciences, LLC
  • Creabilis SA

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • 2B3-201
  • Evasin-3
  • diazoxide
  • NT-KO-009
  • NT-KO-012
  • NT-CC-017
  • VCE-003
  • Antibody for Inflammation
  • artemisinin
  • 5-Methylthiazole Analogs
  • FP7 Project
  • Small Molecule for Inflammation
  • Drugs to Target Deubiquitinating Enzymes for Neuroinflammation
  • Small Molecule For Neuroinflammation
  • Myelin T-reg
  • Drugs to Inhibit 5-Lipoxygenase for Pain and Neuroinflammation

開發中產品的最新趨勢

暫停的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4957IDB

Global Markets Direct's, 'Neuroinflammation - Pipeline Review, H1 2014', provides an overview of the Neuroinflammation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuroinflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroinflammation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neuroinflammation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Neuroinflammation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Neuroinflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Neuroinflammation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Neuroinflammation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Neuroinflammation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neuroinflammation Overview
  • Therapeutics Development
    • Pipeline Products for Neuroinflammation - Overview
    • Pipeline Products for Neuroinflammation - Comparative Analysis
  • Neuroinflammation - Therapeutics under Development by Companies
  • Neuroinflammation - Therapeutics under Investigation by Universities/Institutes
  • Neuroinflammation - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Neuroinflammation - Products under Development by Companies
  • Neuroinflammation - Products under Investigation by Universities/Institutes
  • Neuroinflammation - Companies Involved in Therapeutics Development
    • TxCell SA
    • to-BBB technologies BV
    • St. Charles Pharmaceuticals
    • VivaCell Biotechnology Espana S.L.
    • Neurotec Pharma SL
    • SciFluor Life Sciences, LLC
    • Creabilis SA
  • Neuroinflammation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 2B3-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Evasin-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diazoxide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NT-KO-009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NT-KO-012 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NT-CC-017 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VCE-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody for Inflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • artemisinin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 5-Methylthiazole Analogs - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FP7 Project - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Inflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Target Deubiquitinating Enzymes for Neuroinflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule For Neuroinflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Myelin T-reg - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit 5-Lipoxygenase for Pain and Neuroinflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Neuroinflammation - Recent Pipeline Updates
  • Neuroinflammation - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neuroinflammation, H1 2014
  • Number of Products under Development for Neuroinflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Neuroinflammation - Pipeline by TxCell SA, H1 2014
  • Neuroinflammation - Pipeline by to-BBB technologies BV, H1 2014
  • Neuroinflammation - Pipeline by St. Charles Pharmaceuticals, H1 2014
  • Neuroinflammation - Pipeline by VivaCell Biotechnology Espana S.L., H1 2014
  • Neuroinflammation - Pipeline by Neurotec Pharma SL, H1 2014
  • Neuroinflammation - Pipeline by SciFluor Life Sciences, LLC, H1 2014
  • Neuroinflammation - Pipeline by Creabilis SA, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Neuroinflammation Therapeutics - Recent Pipeline Updates, H1 2014
  • Neuroinflammation - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Neuroinflammation, H1 2014
  • Number of Products under Development for Neuroinflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top